14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AMS vs DXR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (52.2/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin).
Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. AMS 33.8/100 SELL) and 0.28β · 32% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMS vs DXR. Trailing 12-month operating profitability (AMS -7.4% vs DXR -5894.3%) and valuation multiples (AMS 44.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AMS vs DXR Key Questions & Quantitative Answers
As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (52.2/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. AMS trades at $1.07 (44.6x Forward P/E, -7.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. AMS 33.8/100 SELL) and 0.28β · 32% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DXR leads the Growth & Scale pillar: AMS posts +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, AMS generates $30M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, AMS deploys 42.2% of Rev ($13M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.
AMS screens cheaper on headline valuation multiples. AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMS (-12.1% ROE) versus DXR (14.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.